GlassScriptPhysician profile
Amanda M Snow
NPI 1639640063
$13,333.80
in general payments reported to CMS, 2019-2025
24 companies · $3,033 in 2025
The $3,033 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,414 · 2022: $2,304 · 2023: $3,178 · 2024: $3,405 · 2025: $3,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,381 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,380.84 |
| Education | $235.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,029.12 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,542.17 | 2022-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,460.03 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,110.41 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $978.10 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $821.30 | 2022-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $796.56 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $614.92 | 2021-2025 | Trintellix |
| Lundbeck LLC | $603.48 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $575.34 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $484.31 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $406.51 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $353.00 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $251.13 | 2021-2025 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $219.17 | 2025 | Fanapt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $213.89 | 2022-2024 | Jornay Pm |
| Almatica Pharma LLC | $211.17 | 2022-2025 | Gralise, Loreev Xr |
| Tris Pharma INC | $181.61 | 2022-2025 | Dyanavel Xr |
| Corium, LLC | $164.90 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $137.53 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $65.85 | 2023-2024 | Quviviq |
| Indivior INC. | $64.69 | 2022-2025 | Sublocade |
| Bausch Health US, LLC | $27.64 | 2022-2024 | Wellbutrin, Aplenzin |
| Novo Nordisk INC | $20.97 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Snow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.